Want to see NTLA full AI Analyst Report?

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

4,878 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NTLA Analyst Ratings

Hold

5 Buy

6 Hold

3 Sell

Based on 14 analysts giving stock ratings to

Intellia

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NTLA Stock 12 Month Forecast

Average Price Target

$18.92

▲(76.30% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $18.92 with a high forecast of $49.00 and a low forecast of $8.00. The average price target represents a 76.30% change from the last price of $10.73.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","50":"$50","17.75":"$17.75","28.5":"$28.5","39.25":"$39.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$49.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.916666666666668,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,17.75,28.5,39.25,50],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.24,19.68307692307692,22.126153846153844,24.56923076923077,27.012307692307694,29.455384615384617,31.89846153846154,34.34153846153846,36.784615384615385,39.22769230769231,41.67076923076923,44.113846153846154,46.556923076923084,{"y":49,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.24,17.36897435897436,17.497948717948717,17.626923076923077,17.755897435897435,17.884871794871795,18.013846153846153,18.142820512820514,18.27179487179487,18.40076923076923,18.52974358974359,18.65871794871795,18.78769230769231,{"y":18.916666666666668,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.24,16.529230769230768,15.818461538461538,15.107692307692307,14.396923076923077,13.686153846153847,12.975384615384614,12.264615384615384,11.553846153846154,10.843076923076923,10.132307692307693,9.42153846153846,8.71076923076923,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.88,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.49,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.06,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.44,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.27,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.26,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.73,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.24,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$49.00

Average Price Target$18.92

Lowest Price Target$8.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andy Chen

Wolfe Research

Sell

-16.12%

Downside

Downgraded

07/15/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO) and Intellia Therapeutics (NASDAQ: NTLA)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$12→$17

Hold

58.43%

Upside

Reiterated

07/10/26

Intellia Therapeutics (NTLA) Gets a Hold from Wedbush

Whitney Ijem

Canaccord Genuity

$49

Buy

356.66%

Upside

Reiterated

06/16/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Myles Minter

William Blair

―

Buy

―

Reiterated

06/15/26

Analysts' Top Healthcare Picks: Intellia Therapeutics (NTLA), Electrocore (ECOR)

Mitchell Kapoor

H.C. Wainwright

$25

Buy

132.99%

Upside

Reiterated

06/15/26

Intellia: Phase 3 HAELO Success Underpins Buy Rating as Analyst Maintains $25 Price Target

Alec Stranahan

Bank of America Securities

$19

Hold

77.07%

Upside

Reiterated

06/15/26

Analysts Offer Insights on Healthcare Companies: enGene Holdings (NASDAQ: ENGN) and Intellia Therapeutics (NASDAQ: NTLA)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

06/14/26

Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Intellia Therapeutics (NASDAQ: NTLA) and Halozyme (NASDAQ: HALO)

Salveen Richter

Goldman Sachs

Sell

-16.12%

Downside

Reiterated

06/14/26

Sell Rating Maintained on Clinical and Commercial Uncertainty; $9 Price Target Reaffirmed

Debanjana Chatterjee

JonesTrading

$29

Buy

170.27%

Upside

Reiterated

05/27/26

Intellia Therapeutics: Buy Rating Reiterated on De-Risked HAE and ATTR Pipelines; $29 DCF-Based Price Target Maintained

Terence Flynn

Morgan Stanley

$15

Hold

39.79%

Upside

Reiterated

05/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), TriSalus Life Sciences (NASDAQ: TLSI) and Fractyl Health, Inc. (NASDAQ: GUTS)

Brian Cheng

J.P. Morgan

Sell

-25.44%

Downside

Reiterated

05/13/26

J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)

William Pickering

Bernstein

$13→$17

Hold

58.43%

Upside

Assigned

05/13/26

Intellia Therapeutics price target raised to $17 from $13 at BernsteinIntellia Therapeutics price target raised to $17 from $13 at Bernstein

Yanan Zhu

Wells Fargo

$15

Hold

39.79%

Upside

Reiterated

05/12/26

Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)

Luca Issi

RBC Capital

$15

Hold

39.79%

Upside

Reiterated

05/11/26

RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA)

Silvan Tuerkcan

Citizens JMP

$28→$30

Buy

179.59%

Upside

Reiterated

04/28/26

Intellia Therapeutics price target raised to $30 from $28 at CitizensIntellia Therapeutics price target raised to $30 from $28 at Citizens

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andy Chen

Wolfe Research

Sell

-16.12%

Downside

Downgraded

07/15/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (NYSE: BLCO) and Intellia Therapeutics (NASDAQ: NTLA)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$12→$17

Hold

58.43%

Upside

Reiterated

07/10/26

Intellia Therapeutics (NTLA) Gets a Hold from Wedbush

Whitney Ijem

Canaccord Genuity

$49

Buy

356.66%

Upside

Reiterated

06/16/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Myles Minter

William Blair

―

Buy

―

Reiterated

06/15/26

Analysts' Top Healthcare Picks: Intellia Therapeutics (NTLA), Electrocore (ECOR)

Mitchell Kapoor

H.C. Wainwright

$25

Buy

132.99%

Upside

Reiterated

06/15/26

Intellia: Phase 3 HAELO Success Underpins Buy Rating as Analyst Maintains $25 Price Target

Alec Stranahan

Bank of America Securities

$19

Hold

77.07%

Upside

Reiterated

06/15/26

Analysts Offer Insights on Healthcare Companies: enGene Holdings (NASDAQ: ENGN) and Intellia Therapeutics (NASDAQ: NTLA)

Joseph Thome

TD Cowen

―

Buy

―

Reiterated

06/14/26

Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Intellia Therapeutics (NASDAQ: NTLA) and Halozyme (NASDAQ: HALO)

Salveen Richter

Goldman Sachs

Sell

-16.12%

Downside

Reiterated

06/14/26

Sell Rating Maintained on Clinical and Commercial Uncertainty; $9 Price Target Reaffirmed

Debanjana Chatterjee

JonesTrading

$29

Buy

170.27%

Upside

Reiterated

05/27/26

Intellia Therapeutics: Buy Rating Reiterated on De-Risked HAE and ATTR Pipelines; $29 DCF-Based Price Target Maintained

Terence Flynn

Morgan Stanley

$15

Hold

39.79%

Upside

Reiterated

05/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), TriSalus Life Sciences (NASDAQ: TLSI) and Fractyl Health, Inc. (NASDAQ: GUTS)

Brian Cheng

J.P. Morgan

Sell

-25.44%

Downside

Reiterated

05/13/26

J.P. Morgan Remains a Sell on Intellia Therapeutics (NTLA)

William Pickering

Bernstein

$13→$17

Hold

58.43%

Upside

Assigned

05/13/26

Intellia Therapeutics price target raised to $17 from $13 at BernsteinIntellia Therapeutics price target raised to $17 from $13 at Bernstein

Yanan Zhu

Wells Fargo

$15

Hold

39.79%

Upside

Reiterated

05/12/26

Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA)

Luca Issi

RBC Capital

$15

Hold

39.79%

Upside

Reiterated

05/11/26

RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA)

Silvan Tuerkcan

Citizens JMP

$28→$30

Buy

179.59%

Upside

Reiterated

04/28/26

Intellia Therapeutics price target raised to $30 from $28 at CitizensIntellia Therapeutics price target raised to $30 from $28 at Citizens

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Intellia Therapeutics

3 Months

Mani ForooharLeerink Partners

Success Rate

14/39 ratings generated profit

Average Return

+4.67%

Copying Mani Foroohar's trades and holding each position for 3 Months would result in 35.90% of your transactions generating a profit, with an average return of +4.67% per trade.

1 Year

Gena WangBarclays

Success Rate

9/26 ratings generated profit

Average Return

-14.39%

Copying Gena Wang's trades and holding each position for 1 Year would result in 34.62% of your transactions generating a profit, with an average return of -14.39% per trade.

2 Years

Gena WangBarclays

Success Rate

7/26 ratings generated profit

Average Return

-33.51%

Copying Gena Wang's trades and holding each position for 2 Years would result in 26.92% of your transactions generating a profit, with an average return of -33.51% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NTLA Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NTLA has received 9 Buy Ratings, 10 Hold Ratings, and 4 Sell Ratings. NTLA average Analyst price target in the past 3 months is 18.92.

Each month's total comprises the sum of three months' worth of ratings.

NTLA Financial Forecast

NTLA Earnings Forecast

Currently, no earnings data available.

NTLA Sales Forecast

Currently, no sales data available.

NTLA Stock Forecast FAQ

What is NTLA’s average 12-month price target, according to analysts?

Based on analyst ratings, Intellia Therapeutics Inc’s 12-month average price target is 18.92.

What is NTLA’s upside potential, based on the analysts’ average price target?

Intellia Therapeutics Inc has 76.30% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NTLA a Buy, Sell or Hold?

Intellia Therapeutics Inc has a consensus rating of Hold which is based on 5 buy ratings, 6 hold ratings and 3 sell ratings.

What is Intellia Therapeutics Inc’s price target?

The average price target for Intellia Therapeutics Inc is 18.92. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $49.00 ,the lowest forecast is $8.00. The average price target represents 76.30% Increase from the current price of $10.73.

What do analysts say about Intellia Therapeutics Inc?

Intellia Therapeutics Inc’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of NTLA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Intellia Therapeutics (NTLA) Stock Forecast & Price Target

NTLA Analyst Ratings

NTLA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Intellia Therapeutics

NTLA Analyst Recommendation Trends

NTLA Financial Forecast

NTLA Earnings Forecast

NTLA Sales Forecast

NTLA Stock Forecast FAQ

Detailed List of Analyst Forecasts